Click Here to
Subscribe
Breaking
News, Updates,
& More
Stay Up
to Date

Combination Therapy Produced Strong Results for Late-Stage Ovarian Cancer Patients

Late-stage ovarian cancer patients responded well to an experimental carboplatin/decitabine combination therapy, even though they had become resistant to carboplatin, Indiana University researchers report. Furthermore, the researchers believe they have discovered biomarkers that could assist in identifying patients who are most likely to benefit from this therapy. 

The carboplatin/decitabine drug combination produced a positive result in 70% of patients in this phase 2 trial. The combination was tolerated well and did not produce any dose-limiting toxicities. In 12 of 17 carboplatin-resistant patients whose cancer was progressing, tumor growth slowed considerably or stopped altogether patients following treatment with the experimental drug combination. Moreover, 1 woman’s tumor became undetectable; however, at 336 days her cancer progression resumed. At 6 months, 9 women were still in remission.

Related Items
Skin Cancer Screening at Your Fingertips
TON - Daily published on July 18, 2012 in Gynecologic Cancers
Combination Therapy Produced Strong Results for Late-Stage Ovarian Cancer Patients
TON - Daily published on August 4, 2011 in Gynecologic Cancers
Telephone Support Increases Adherence to IV Chemotherapy for Recurrent Ovarian Cancer
Fran Lowry
Web Exclusives published on December 10, 2010 in Gynecologic Cancers, In the News
Last modified: September 8, 2015